Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

This study has been completed.
Information provided by (Responsible Party):
MedImmune LLC Identifier:
First received: October 19, 2012
Last updated: February 1, 2016
Last verified: February 2016
A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.

Condition Intervention Phase
Rheumatoid Arthritis
Biological: mavrilimumab subcutaneous Injection
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: Informed consent through to approximately 5 year total ]
    The occurrence of AEs and SAEs

  • Safety and Tolerability [ Time Frame: Various timepoints from Day 1 through to approximately 5 years ]
    Vital sign measurements - blood pressure, heart rate, temperature, respiratory rate

  • Safety and Tolerability [ Time Frame: From Day 1 (pre-dose) through to approximately 5 year total ]
    Clinical lab measurements - chemistry and hematology

  • Safety and Tolerability [ Time Frame: From Day 1 (pre-dose) through to approximately 5 year total ]
    Pulmonary function tests and dyspnoea score

Enrollment: 409
Study Start Date: December 2002
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mavrilimumab Q2W + MTX
GM-CSFR alpha inhibitor
Biological: mavrilimumab subcutaneous Injection
GM-CSFR alpha inhibitor

Detailed Description:
Despite the therapeutic improvements with recent biologic agents approved for rheumatoid arthritis (RA), there is still significant unmet medical need for the treatment of subjects with this chronic disease to achieve a faster, more complete response, and higher rates of remission. This study is an open-label extension study for subjects who have participated in one of the qualifying development program studies with mavrilimumab. Participation in this study will allow these subjects to continue to receive long-term treatment with mavrilimumab. The data from this study will provide an evaluation of the long-term safety of mavrilimumab in adult subjects with RA. In addition, long-term exploratory efficacy outcomes such as joint damage and disability will be evaluated.

Ages Eligible for Study:   18 Years to 150 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who have completed the treatment period of the qualifying study or will have failed to respond adequately to investigational product at a predefined time point in the qualifying study regardless of their initial randomization.
  • No evidence of clinically uncontrolled respiratory disease to be confirmed by a local pulmonologist

Exclusion Criteria:

  • Subjects who have been permanently discontinued from investigational product in previous qualifying study.
  • Any new conditions or worsening of any pre-existing conditions as defined in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01712399

  Show 54 Study Locations
Sponsors and Collaborators
MedImmune LLC
  More Information

Responsible Party: MedImmune LLC Identifier: NCT01712399     History of Changes
Other Study ID Numbers: CD-IA-CAM-3001-1109
Earth Explorer X ( Other Identifier: MedImmune )
Study First Received: October 19, 2012
Last Updated: February 1, 2016

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017